◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral SKIP-PERMANENT HIGH

Tianeptine

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-PERMANENT HIGH

Functionally an opioid antidepressant masquerading as a "nootropic" — at biohacker doses (250-4000+ mg/day vs 37.5 mg therapeutic) it is opioid-class abuse with full dependence, withdrawal, respiratory depression, and death; non-opioid alternatives exist for every plausible use case. Nothing realistic would change this.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-PERMANENT HIGH

    No cognitive enhancement evidence; opioid dependence in a developing brain is a worst-case scenario; the AMPA/BDNF neuroplasticity claim is achievable via TAK-653, ketamine, or even SSRIs without the opioid receptor activation.

  • 30-50, executive maintenance
    SKIP-PERMANENT HIGH

    Same logic. If treatment-resistant depression emerges, ketamine/esketamine and proper psychiatric care are the answer, not unsupervised tianeptine.

  • 50+, mild cognitive decline
    SKIP-PERMANENT HIGH

    Opioid + elderly = falls, respiratory depression, constipation, cognitive worsening. Worse risk profile, not better.

  • Anxiety-prone
    SKIP-PERMANENT HIGH

    The anxiolysis is real and seductive — that's exactly why it traps anxiety patients. Buspirone, SSRIs, agomelatine, propranolol, magnesium, theanine all hit anxiety without opioid receptors.

  • DylanHigh athletic load, tested status (irrelevant for Dylan but for completeness)
    SKIP

    Not on WADA list per se but respiratory depression + opioid dependence + match-day testing detection is a career risk.

  • Sleep-disordered
    SKIP-PERMANENT HIGH

    It will sedate you. It will also wake you up at 3 AM in early withdrawal once dependence sets in. Daridorexant, trazodone, magnesium, glycine, sleep hygiene are non-opioid options.

  • Recovery-focused (post-injury, post-illness)
    SKIP-PERMANENT HIGH

    Tempting use case (mood + anxiolysis + analgesia during injury recovery) — and exactly the on-ramp to opioid use disorder. BPC-157, TB-500, pregabalin (with caution), or supervised short-course Rx opioid for acute pain are better.

  • Strength/anabolic-focused
    SKIP

    Not relevant; opioids suppress HPG axis with chronic use.

  • Treatment-resistant depression (the most defensible use case)
    STILL

    SKIP for biohacker self-treatment. Under a French/EU psychiatrist with monitoring, 37.5 mg/day Stablon is a defensible second-line agent. For Dylan — a 20yo without a depression diagnosis, without trial of front-line agents, without supervision, and without access to the supervised regulatory framework — the answer is no. Ketamine therapy, TMS, MAOI under MD supervision, or proper SSRI/SNRI trial all come first. Better non-opioid options exist for every realistic use case.

▸ Subjective experience (deep)

At Rx therapeutic dose (12.5 mg × 3/day, French label):

  • Mood-lift over 1-2 weeks comparable to SSRI onboarding
  • Mild calming/anxiolysis
  • Most people don't get acute "high" at this dose — feels like an antidepressant
  • Withdrawal still possible if escalated or used long-term

At biohacker / gas-station doses (50 mg → 2000+ mg per day, often divided q3-4h):

  • Classical opioid euphoria — warm, blanket-like, body-relaxation, "everything is fine"
  • Anxiolysis and mood-bright far beyond the therapeutic dose
  • Pinpoint pupils at high doses
  • Itching (histamine release, classical opioid sign)
  • "Nodding" / sedation at very high doses
  • Crash 2-3 hours later → redose to avoid early withdrawal → tolerance climbs steeply within days to weeks → the user is now physically dependent on a μ-opioid agonist with a short half-life and is redosing 6-12+ times a day
  • Withdrawal at this point is full opioid withdrawal: bone aches, chills, diarrhea, anxiety crisis, autonomic storm, insomnia, intense cravings, lasting 5-14 days for acute phase + months of PAWS

Honest framing: if a biohacker took tianeptine sulfate 100 mg and gave a clean trip report, they would describe an opioid experience. They'd just call it "warm mood" or "anti-anxiety glow" because they don't realize they're describing an opioid.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Fast (opioid-class). Days to weeks at recreational doses; months at therapeutic doses. Cross-tolerance with other μ-opioid agonists.
  • Recommended cycle: None. This is not a cycle-able compound; the half-life is 2.5-3 hours (sodium) or somewhat longer (sulfate), forcing q3-6h dosing → every-day-dependence physiology.
  • Reset protocol: If physically dependent, this is a medical detox, not a "reset." Buprenorphine/methadone-assisted taper, ideally inpatient or close outpatient supervision. Do not attempt cold turkey at high doses without medical support — autonomic storm is dangerous.
▸ Stacking deep dive

Synergistic with

  • None should be considered. All "synergies" amount to "stacking opioids with other CNS depressants" → respiratory depression risk multiplies.

Avoid stacking with (REAL DANGER)

  • kratom — mitragynine + 7-OH-mitragynine are also μ-opioid agonists. Co-use is the most common pattern in tianeptine fatality case series. Stacking μ-agonists is how people die.
  • phenibut — GABA-B agonist + μ-opioid agonist = compounded sedation, respiratory depression, and two simultaneous severe withdrawals if both are run chronically. This is the worst-of-both-worlds biohacker stack.
  • Any opioid (Rx or otherwise) — additive μ-agonism, additive respiratory depression.
  • Benzodiazepines, Z-drugs, GHB/GBL, alcohol, gabapentinoids — additive respiratory depression. The CDC respiratory-depression-death warning for opioid + benzo applies fully.
  • MAOIs — historically contraindicated; risk of serotonin/hypertensive interaction unclear given the corrected mechanism, but the warning stands.
  • Tramadol, tapentadol — both have opioid + monoamine effects; stacking is doubly bad.

Neutral / safe co-administration

Not applicable. The compound itself is the problem.

▸ Drug interactions deep dive
  • Hepatic metabolism via β-oxidation (not CYP450-heavy), so classical CYP induction/inhibition interactions are mild.
  • Pharmacodynamic interactions are the issue: any other CNS depressant is dangerous (see above).
  • Naloxone fully reverses overdose — this is diagnostic of the opioid mechanism and should be the standard ED intervention.
  • No clean interaction with hormonal contraceptives, statins, antibiotics, etc. (CYP profile is mild) — but this is largely irrelevant given the verdict.
▸ Pharmacogenomics
  • No major CYP-based pharmacogenomic gating (β-oxidation primary route).
  • OPRM1 A118G polymorphism (μ-opioid receptor) likely modulates subjective response and dependence risk, as it does for all μ-agonists — carriers of the G allele may experience reduced euphoria but the addiction physiology still applies.
  • Not actionable for prevention; just confirms it behaves like every other μ-opioid agonist.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US gas station / smoke shop ("Zaza Red," "Tianna Red," "TD Red," "Neptune's Fix," "Pegasus") Convenience stores $10-40 per package Variable ILLEGAL in 15+ states (MI, AL, MN, TN, GA, IN, KY, OH, FL, MS, NC, LA, VA, DE, TX 2025); FDA actively warning + recalling; products frequently adulterated with kratom, synthetic cannabinoids, or higher-than-labeled tianeptine doses
French / Indian / Eastern European Rx (Stablon, Coaxil, Tatinol, 12.5 mg) International online pharmacies (InhousePharmacy.vu, LifeRx) ~$30-60 / 60 tablets Medium-high for product, regulatory gray zone Real Servier-or-generic product; importation legality questionable in US without Rx; this is the "supervised antidepressant" use case — still SKIP for nootropic purposes
Research-chem powder (sulfate or sodium) Various RC vendors $30-100 / 5-10g Low-medium; COA quality variable Highest abuse-risk route — bulk powder + scale = escalation. The Kimera-tier RC vendors do not sell this; the ones that do are typically lower-tier.
Underground market Street n/a n/a Increasingly common in opioid-use-disorder populations as a substitute when fentanyl/heroin supply tightens

For Dylan: none of these paths should be used. Even the "legal Rx from France" path is a SKIP for a 20yo MMA athlete with no diagnosed depression and no resistance to the front-line non-opioid antidepressants he hasn't tried.

▸ Biomarkers to track (deep)
  • Baseline (before starting): Not applicable — recommendation is don't start. If supervised Rx use is happening: LFTs (ALT/AST), vitals, opioid use history screen, depression severity (PHQ-9), benzodiazepine/alcohol screen.
  • During use: LFTs every 3-6 mo, weight (anorexic effect uncommon but reported), vitals, opioid dependence screen. Should be physician-managed.
  • Post-cycle: Not a cycle-able compound.
▸ Controversies / open debates Live debate
  • The mechanism reversal (2014-2025) is the central story. For 30+ years Servier marketed tianeptine as a "selective serotonin reuptake enhancer" — a unique antidepressant mechanism. The Gassaway 2014 Translational Psychiatry paper showed it was actually a μ-opioid agonist, and every replication since has confirmed this. The pharmacology textbooks still frequently cite the older mechanism. It is an opioid antidepressant. Biohackers who read the pre-2014 literature may have an outdated mental model.
  • "Is the European supervised use safe?" At 37.5 mg/day with monitoring, low-dependence-risk patients can use tianeptine for years and discontinue with a taper. The withdrawal warning Servier added in 2007 reflects that even at this dose, escalation and dependence happen in some users. Defensible under medical supervision; not defensible as a biohacker self-administered nootropic.
  • "Isn't kratom worse?" Kratom has a more complex receptor profile (partial agonism + biased agonism at 7-OH-mitragynine) and arguably a less linear dependence curve. Tianeptine is a cleaner full agonist and clinically presents as a more straightforward opioid use disorder. Both are SKIP. Stacking them (common gas-station co-purchase) is a documented fatality pattern.
  • "What about the AMPA/BDNF neuroplasticity story?" Real, but MOR-dependent in every published knockout/antagonist study. You cannot get the upside without the opioid receptor activation. If neuroplasticity is the goal, ketamine, psilocybin (where legal), TAK-653, or even classical antidepressants achieve it without μ-opioid agonism.
  • Where my prior verdict might be wrong: I do not think it is. Even the most charitable reading (supervised 12.5 mg TID for treatment-resistant anxious depression in a non-addiction-history patient under a French psychiatrist) is not a biohacker recommendation, and Dylan does not fit any of those criteria.
▸ Verdict change log
  • 2026-05-05 — SKIP-PERMANENT HIGH (initial verdict). Functionally an opioid antidepressant; biohacker doses are opioid abuse with full dependence/withdrawal/death risk; non-opioid alternatives exist for every plausible use case. Confirmed prior encyclopedia (2026-05-05) verdict with deeper research pass. Nothing realistic would change this.
▸ Open questions / gaps Open
  • Long-term outcomes in heavy users post-detox — what fraction relapse, what fraction develop other opioid use disorders, what neurological residue. Limited follow-up data; opioid-class outcome literature is the best proxy.
  • Whether there exists a μ-opioid biased agonist that captures the antidepressant effect without the addiction profile — active research area (PZM21 and other "G-protein biased" agonists) but none are tianeptine-shaped.
  • Whether the AMPA/BDNF effects can be unbundled from MOR — current knockout data says no, but this is an active question.

What would change the verdict: nothing realistic. If a biased μ-agonist with antidepressant efficacy and no abuse liability is developed, that's a different compound, not tianeptine. The compound itself, in the hands of biohackers, will remain SKIP-PERMANENT.

▸ Sources (full, with our context)
Back to compact view